Clinical Trial Update: FMT in IT-refractory HCC - FAB-HCC Pilot Study [Phase 2]

View source ↗

Summary

Phase 2 FAB-HCC Pilot Study completed evaluating fecal microbiota transplant for hepatocellular carcinoma that is refractory to immune therapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Fecal microbiota transplant (fecal microbiota transplant)

Snippet

Sponsor: Medical University of Vienna | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: COMPLETED